| Sample Size (%) |
---|---|
Total number of participants | 2,481,887 |
Number of healthcare workers | 945 (0.3%) |
Number of older adults | 2,480,9422,481,887 (99.7%) |
Number of studies included | n = 39 |
Study Location | |
 United States | 30/39 (76.9%) |
 Singapore | 3/39 (7.7%) |
 Japan | 2/39 (5.1%) |
 Canada | 1/39 (2.6%) |
 Hong Kong | 1/39 (2.6%) |
 Australia | 1/39 (2.6%) |
 Germany | 1/39 (2.6%) |
Study Design | |
 Interventional | 34/39 (87.2%) |
 Controlled | 15/34 (44.1%) |
 Randomized | 5/34 (14.7%) |
 Observational | 5/39 (12.8%) |
Type of pneumococcal vaccine | |
 PPV23 | 7/39 (17.9%) |
 PVC13 | 1/39 (2.6%) |
 Both PVC13 and PPV23 | 14/39 (35.8%) |
Outcome Measures | |
 Vaccination rates | n = 34 |
 Information or awareness scores | n = 9 |
 Implementation outcomes | n = 6 |
Pillar according to European Union Conceptional Framework for Action | |
 Information campaigns | n = 15 |
 Prioritization of vaccination schemes | n = 14 |
 Primary care interventions | n = 10 |